Dispensary owner optimistic after Trump eases marijuana restrictions

President Trump signed an executive order to expedite reclassification of marijuana from Schedule I to Schedule III, a move that would allow federal tax deductions, expand medical research and reduce stigma for state-legal cannabis businesses. Dispensary owner Joseph Pattah (Mango Cannabis, Henrietta, N.Y.) said operating costs can be “easily half a million” per month and that rescheduling would permit normal business write-offs and payroll flexibility; New York’s Office of Cannabis Management welcomed the step but noted DEA final approval is required and federal banking and criminal-justice barriers remain.

Analysis

Market structure: Rescheduling materially favors licensed U.S. operators (MSOs), ancillary service providers, and cannabis-focused REITs because removal from Schedule I would likely relax 280E constraints and lower effective federal tax rates (I estimate a 10–25 percentage-point reduction in after-tax cash drag for compliant operators). Well-capitalized MSOs and IIPR-type landlords gain pricing power and M&A optionality; smaller cash-strapped operators and shadow-market sellers face greater consolidation pressure. Cross-asset: expect tightening in high-yield spreads for cannabis credits, modest CAD pressure (Canada’s large LPs face tougher U.S. competition), and a short-lived spike in equities/ETF vols.

Risk assessment: Key tail risks are DEA refusal or indefinite delay, legal injunctions, or Congress/IRS maintaining 280E-like tax treatment despite rescheduling — assign a 30–50% probability that meaningful federal relief (final DEA rule + IRS guidance) arrives within 6–12 months. Near-term (days–weeks) will be headline-driven volatility; medium-term (3–12 months) depends on regulatory milestones; long-term (1–3 years) is consolidation and margin expansion if banking and tax follow-through occurs. Hidden dependency: banking access and state-federal rule alignment are the gating factors — without them equity upside is capped.

Trade implications: Tactical overweight in diversified exposure (ETF MJ) and selective longs in IIPR (real estate yield play) while favoring well-capitalized U.S. MSOs (e.g., TLRY/CRON if exposure desired) — size 1–3% position each and scale. Use 9–15 month 25–35% OTM call spreads on MJ or IIPR to play the regulatory path with defined risk; consider pair trade long IIPR vs short CAD large-cap LPs (CGC) to capture U.S. regulatory beta. Entry on pullbacks of 10–20%; exit or hedge if DEA misses a 6–12 month window.

Contrarian angles: Market likely underprices banking and tax implementation lags; consensus optimistically conflates rescheduling with immediate banking/open capital markets. Historical parallel: Canada’s post-legalization drawdown when supply surged and capital was misallocated — expect potential 20–40% margin compression in some state markets as supply increases before retail demand normalizes. Unintended consequence: faster capital inflows could accelerate price competition, so avoid uncovered long-duration bets on small MSOs.

Key Decisions for Investors

• Establish a 2–3% portfolio position in ETFMG Alternative Harvest ETF (MJ) over 4–8 weeks, using buy on 10–15% pullbacks; hedge with 9–12 month 30% OTM puts sized at 25% notional to protect regulatory downside.
• Allocate 1–2% to Innovative Industrial Properties (IIPR) equity or 1.5–2.5% to IIPR via 12-month 25–35% OTM call spread (buy calls 25–35% OTM / sell 55–65% OTM) to capture repricing of cannabis real estate yields if DEA & IRS finalize relief within 6–12 months.
• Implement a pair trade: long IIPR (1% position) and short 1–1.5% in Canadian large-cap LPs (CGC or TLRY depending on liquidity) to express U.S. regulatory upside vs Canadian competitive pressure; rebalance if IIPR outperforms by >20% or if DEA misses a 12-month milestone.
• Avoid broad bank exposure as a lever to this trade; instead monitor three catalysts over next 90 days—(1) DEA timeline announcement, (2) IRS guidance on 280E, (3) any Senate banking bill—if all positive, increase cannabis allocation by another 1–2% within 30 days.